Patients who had early discontinuation of prophylaxis for pneumocystosis were associated with a higher risk of pneumocystosis and bacterial infections than those who continued prophylaxis until CD4 increased to ≧200 cells/μL after HAART. This evidence concerns the gene CD4 and pneumocystosis.